OGEN - Oragenics gains after final toxicology data for intranasal COVID vaccine

• Nanocap biotech Oragenics ( NYSE: OGEN ) added ~37% pre-market Thursday issuing pre-clinical findings from a final toxicology report to highlight the safety of its intranasal vaccine candidate for COVID-19, NT-CoV2-1.
• Citing a toxicology study for NT-CoV2-1 in rabbits, Oragenics ( OGEN ) said the vaccine candidate resulted in no toxicity signals or adverse events even after repeated administration at the maximum dose that the company intends to use for its human study.
• Oragenics ( OGEN ) expects that findings in the final toxicology report will support its plans to start regulatory submissions to begin a Phase 1 clinical trial for NT-CoV2-1.
• The company intends to update investors on its regulatory plans for the candidate in Q1 2023.
• In August, Oragenics ( OGEN ) announced initial data from the study ahead of the final toxicology report.

For further details see: